Le Lézard
Classified in: Health, Covid-19 virus
Subject: IMA

Health Canada now authorizes Dolphin Vagal Nerve Stimulator (VNS) for emergency use in the acute treatment of adult patients with known or suspected COVID-19


TORONTO, April 13, 2021 /CNW/ - Covid-19 is an infectious disease that may lead to Acute Respiratory Distress Syndrome (ARDS) and respiratory dysfunction (Liu 2017).  Science recognizes that Covid-19 ARDS' excessive mortality rates are due to the medical establishment's inability to resolve inflammatory responses, causing multi-organ failure (Kaniusas 2020).

Health Canada approves Dolphin VNS as 1st medical device to treat COVID-19 respiratory distress.

Dolphin Vagus Nerve Stimulation activates our Immune System  
The vagus nerve, the major nerve of the parasympathetic nervous system, controls our immune response to inflammation (Pavlov 2012), and pulmonary (breathing ) functioning (Chang 2015).  Dolphin Vagal Nerve Stimulation has been proven in science to enhance the parasympathetic system (Armstrong 2019), reducing lung inflammation (Kaniusas 2019) and  pro-inflammatory cytokines to improve respiratory functioning (Tracey 2007).

With more than 1 million COVID-19 cases reported in Canada and our ICU medical system nearing capacity (due to COVID-19 Acute Respiratory Disorder), the country needs a safe, effective means to reduce the heavy societal costs of COVID-19 related respiratory distress within the hospital setting. Health Canada agrees the severity of COVID-19 ARDs can be only be reduced by enhancing parasympathetic vagal tone, and Dolphin VNS is currently the only device on the market able to perform this function.

Dolphin Vagal Stimulator COVID-19 Application Scenarios::

Dolphin VNS is a safe clinical procedure and could be an effective treatment for ARDS originated by Covid-19 and similar viruses. Dolphin VNS enables the introduction of a potentially lifesaving intervention which can be safely administered by any health care professional or clinical staff with minimal training or supervision.  Dolphin VNS can help our current crisis.

"3rd COVID wave strains Ontario ICU's"

"Canada now surpasses USA COVID rate"

"Situation in Ontario ICUs looking dire "

Dolphin Vagal Stimulator kit
The Dolphin Vagal Nerve Stimulator (VNS) Kit comes with Dolphin device, protocol manual and instructions for easy application.  Dolphin Vagal Nerve Stimulator (VNS) Kit retails for $749.00 and may be purchased directly on the company's website

SOURCE Dolphin Neurostim


These press releases may also interest you

at 16:10
The global consumer healthcare market size is estimated to grow by USD 170.2 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.78% during the forecast period. Awareness about lifestyle diseases is driving...

at 16:01
On the Fourth of July, American Independence Day, the American Association of Kidney Patients (AAKP) announced the rapid success and growing impact of its 2024 non-partisan KidneyVotertm registration drive. On June 19, Flag Day, AAKP kicked off its...

at 15:20
Team famous for HIV breakthroughs demonstrates both persistent COVID virus and widespread immune activation in long COVID; provides clear targets for treatment Key points: SARS-CoV-2 double-stranded RNA indicative of viral replication was found in...

at 15:10
The Board of Directors of FS Credit Opportunities Corp. (the Fund) announced the monthly distribution for July 2024. The distribution of $0.06 per share will be paid on July 31, 2024. Further information on the distribution is summarized in the...

at 15:00
Key PointsLance Foos, an Ohio National Guard Brigade Plans Officer and Marathon Petroleum employee, balanced military duties with civilian responsibilities, showcasing resilience and dedication.Throughout challenging times of deployment, Foos's...

at 14:55
The global anti-inflammatory therapeutics market size is estimated to grow by USD 38.7 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 6.3% during the forecast period. Increase in off-label use is...



News published on and distributed by: